Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dyston versus Dysport for chronic migraine in adults
IRCT20201104049265N3Phase 3Completed
- Sponsor
- Imen Vaccine Alborz
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic migraine comparing Dyston with Dysport (2 arms). Primary endpoint: 50% responder rate. Started Jan 2022; status: completed.
02
Drugs
Onabotulinumtoxina + hydrogelbotulinum toxin type A
03
Conditions
chronic migraine
Beyond the preview
Go deeper on IRCT20201104049265N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201104049265N3.